NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Co (BMY) announced that FDA lifted a partial clinical hold placed on CA209-602 (CheckMate -602), a randomized, open-label Phase 3 study evaluating th...
Original Article: Bristol-Myers Squibb: FDA Action Removes Partial Hold On CheckMate -602